NCT00534144

Brief Summary

This study will compare the effects of sodium ferric gluconate complex and iron sucrose on urine concentrations of various chemicals including protein

Trial Health

90
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
74

participants targeted

Target at P75+ for phase_1

Timeline
Completed

Started Sep 2007

Geographic Reach
2 countries

13 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2007

Completed
19 days until next milestone

First Submitted

Initial submission to the registry

September 20, 2007

Completed
4 days until next milestone

First Posted

Study publicly available on registry

September 24, 2007

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2008

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2008

Completed
Last Updated

September 23, 2011

Status Verified

September 1, 2011

Enrollment Period

1.2 years

First QC Date

September 20, 2007

Last Update Submit

September 22, 2011

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change in urine protein

    6 weeks

Study Arms (2)

Iron Sucrose

ACTIVE COMPARATOR
Drug: iron sucrose injection, USP

Ferric Gluconate

ACTIVE COMPARATOR
Drug: sodium ferric gluconate complex in sucrose injection

Interventions

iron sucrose injection, USP, 100 mg intravenously (IV) per week, for 5 weeks

Iron Sucrose

sodium ferric gluconate complex in sucrose injection, 100 mg intravenously (IV) per week, for 5 weeks

Ferric Gluconate

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Moderate to severe anemia
  • Iron deficiency
  • Moderate to severe chronic kidney disease, not receiving dialysis
  • Age ≥ 18 or greater and able to give informed consent

You may not qualify if:

  • Known sensitivity to Sodium Ferric Gluconate Complex in Sucrose Injection, Iron sucrose USP, or any of their components
  • Clinically unstable
  • Indication of iron sufficiency
  • Bladder obstruction conditions that would not allow for good urine output

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (13)

Unknown Facility

Phoenix, Arizona, United States

Location

Unknown Facility

Alhambra, California, United States

Location

Unknown Facility

Bell Gardens, California, United States

Location

Unknown Facility

Exeter, California, United States

Location

Unknown Facility

Glendale, California, United States

Location

Unknown Facility

Visalia, California, United States

Location

Unknown Facility

Fort Lauderdale, Florida, United States

Location

Unknown Facility

Hines, Illinois, United States

Location

Unknown Facility

Shreveport, Louisiana, United States

Location

Unknown Facility

Boston, Massachusetts, United States

Location

Unknown Facility

Houston, Texas, United States

Location

Unknown Facility

Fairfax, Virginia, United States

Location

Unknown Facility

San Juan, Puerto Rico

Location

Related Publications (1)

  • Agarwal R, Leehey DJ, Olsen SM, Dahl NV. Proteinuria induced by parenteral iron in chronic kidney disease--a comparative randomized controlled trial. Clin J Am Soc Nephrol. 2011 Jan;6(1):114-21. doi: 10.2215/CJN.06020710. Epub 2010 Sep 28.

MeSH Terms

Conditions

Kidney Failure, ChronicAnemia, Iron-Deficiency

Interventions

Ferric Oxide, Saccharatedferric gluconateSucrose

Condition Hierarchy (Ancestors)

Renal Insufficiency, ChronicRenal InsufficiencyKidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and SymptomsAnemia, HypochromicAnemiaHematologic DiseasesHemic and Lymphatic DiseasesIron DeficienciesIron Metabolism DisordersMetabolic DiseasesNutritional and Metabolic Diseases

Intervention Hierarchy (Ancestors)

Ferric CompoundsIron CompoundsInorganic ChemicalsGlucaric AcidSugar AcidsAcids, AcyclicCarboxylic AcidsOrganic ChemicalsHydroxy AcidsCarbohydratesDisaccharidesOligosaccharidesPolysaccharidesSugars

Study Officials

  • Naomi V. Dahl, Pharm.D.

    Watson Laboratories, Inc.

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 20, 2007

First Posted

September 24, 2007

Study Start

September 1, 2007

Primary Completion

November 1, 2008

Study Completion

November 1, 2008

Last Updated

September 23, 2011

Record last verified: 2011-09

Locations